anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Phthalates are common endocrine disruptors. The placental barrier can be crossed by phthalates and may have a negative impact on the health of the fetus. However, the association between prenatal exposure to phthalates and birth size is still debatable. Here, we performed this meta-analysis to assess the relationship between prenatal phthalates exposure and birth size. Eighteen studies were finally included by searching PubMed, Embase, Scopus, Ovid, and Web of Science databases and standardized regression coefficients and standard errors were used to pool effect size. Our results showed that prenatal exposure to MMP (=-0.04, 95%CI: -0.08, -0.01) and MEP (=-0.01, 95%CI: -0.01, -0.002) was significantly associated with birth weight. However, no significant associations were identified for phthalate exposure with birth length, head circumference and chest circumference. Because the limiting of studies, more high-quality case-control studies or cohort studies are urgently needed to draw the best conclusions.
1. Technical Result Strengthening of therapeutic properties. 2. Essence A compound of the formula (I) (wherein R1, R2, R7 and A are disclosed in the description) or pharmaceutically acceptable salt or a solvate thereof, the method for the preparation pharmaceutical composition containing the same and the use thereof in medicine for preparation of medicaments. 3. Field of Application Medicine.
Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
PROBLEM TO BE SOLVED: To obtain an emulsified cosmetic with natural, nonwhitish transparent feeling, having high ultraviolet-blocking ability, and affording a makeup finish having emphasized three-dimensional effect by combining titanium oxide-coated mica of specific particle size with a specific silicone suspension. SOLUTION: This emulsified cosmetic is obtained by including (A) pref. 1-30 wt.% of titanium oxide-coated mica with an average particle size of <=30 μm (pref. hydrophobized one) and (B) a silicone suspension of titanium oxide microparticles and/or zinc oxide microparticles; wherein the average size of the primary particles of the titanium oxide or zinc oxide microparticles in the component B is pref. 0.001-1.0 μm, the concentration of the microparticle powder in the suspension is 0.1-40 wt.%, and the silicone oil to disperse the microparticles is pref. octamethylcyclotetrasiloxane, polyether-modified silicone or the like. For this cosmetic, the appearance can be made colorless by selecting ingredients to be formulated.
The exercise involved jumping on the mini trampoline with feet slightly apart. Participants stood on the mid portion of the trampoline bed and made repeated up-and-down bouncy movements. Each foot strike equals one step or bounce. With each landing, the mat of the trampoline underwent deformation and the springs released the energy stored in them such that the participant was made to bounce off the mat. Exercise was administered for between 10 - 15 minutes after which a 5-minute period of rest was allowed. A heart rate monitor was used to guide the intensity of the exercise in the moderate range. Each participant accumulated between 20 and 30 minutes of rebound exercise (bouncing on a mini trampoline) per session, administered three times per week for 12 weeks. All data were captured at baseline and at the end of the 12-week intervention period.
The present invention relates to the provision of means and methods for the generation of novel mosaic bacteriophages and the methods of using the same, including medical and non-medical uses. More specifically, the invention relates to a method of breeding a combination of ancestor bacteriophages comprising a first ancestor bacteriophage, a second ancestor bacteriophage and a third ancestor bacteriophage whereby these ancestor phages are selected from 812/K-like bacteriophages and from ISP-like bacteriophages. The inventive (mosaic) bacteriophages obtainable by the means and methods provided herein comprise a genome/nucleotide sequence which comprises at least one genome fragment/nucleotide sequence of said first ancestor bacteriophage, at least one genome fragment/nucleotide sequence of said second ancestor bacteriophage and at least one genome fragment/nucleotide sequence of said third ancestor bacteriophage. The inventive (mosaic) bacteriophages are,  inter alia , useful as pharmaceuticals, particularly for the medical intervention in bacterial infections, also comprising implant- associated infections. The mosaic bacteriophages are in a particular embodiment useful for treating  Staphylococcus aureus  infections but also their use in non-medical methods,  e.g.  of killing and/or inhibiting the growth of bacteria, particularly on a surface, is part of in the present invention.
It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
Acute scrotum in a child is common, and the main underlying conditions are torsion of intrascrotal appendages, epididymitis, testicular torsion and idiopathic scrotal edema. The main diagnostic aim is to confirm or rule out testicular torsion, since this may lead to irreversible ischemia within hours. The diagnostics can be difficult, especially in prepubertal boys, but consist of a thorough history and clinical examination, the use of a clinical prediction score, and sometimes ultrasound with doppler. However, none of these tools can with completely accuracy rule out a testicular torsion, and uncertainty should prompt an acute scrotal exploration. The treatment of a testicular torsion is detorsion and bilateral orchidopexy, or unilateral orchidectomy in case of a completely necrotic testicle. Treatment of the other underlying conditions is often only symptomatic, and follow-up is often not required.
BACKGROUND AND AIMS: Patients with atrial fibrillation (AF) are at increased risks of cardiovascular diseases and mortality, but risks according to age at diagnosis have not been reported. This study investigated age-specific risks of outcomes among patients with AF and the background population.
METHODS: This nationwide population-based cohort study included patients with AF and controls without outcomes by the application of exposure density matching on the basis of sex, year of birth, and index date. The absolute risks and hazard rates were stratified by age groups and assessed using competing risk survival analyses and Cox regression models, respectively. The expected differences in residual life years among participants were estimated.
RESULTS: The study included 216 579 AF patients from year 2000 to 2020 and 866 316 controls. The mean follow-up time was 7.9 years. Comparing AF patients with matched controls, the hazard ratios among individuals ≤50 years was 8.90 [95% confidence interval (CI), 7.17-11.0] for cardiomyopathy, 8.64 (95% CI, 7.74-9.64) for heart failure, 2.18 (95% CI, 1.89-2.52) for ischaemic stroke, and 2.74 (95% CI, 2.53-2.96) for mortality. The expected average loss of life years among individuals ≤50 years was 9.2 years (95% CI, 9.0-9.3) years. The estimates decreased with older age.
CONCLUSIONS: The findings show that earlier diagnosis of AF is associated with a higher hazard ratio of subsequent myocardial disease and shorter life expectancy. Further studies are needed to determine causality and whether AF could be used as a risk marker among particularly younger patients.
This invention provides carbohydrate epitope mimic compounds, particularly peptides, and analogs and variants thereof. In particular, the compounds and  peptides of the present invention mimic the carbohydrate epitope GlcA.beta.1→3Gal.beta.1→4GlcNAc or sulfate - 3GlcA.beta.1→3Gal.beta.1→4GlcNAc, or the L2/HNK1 carbohydr ate epitope. This invention provides an isolated peptide comprising an amino aci d sequence of a carbohydrate epitope mimic peptide in which the amino acid sequence is set forth in any of SEQ ID NOS: 1-8, 27-38, 39, 40 and 41, including variants, analogs and active fragments thereof. The invention further provides an isolated nucleic acid encoding a peptide comprising an amino acid sequence of a carbohydrate epitope mimic peptide. This invention provides pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids, particularly in modulati ng or mediating cell-cell adhesion and viral infection and the processes and events mediated thereby. Assays for compounds which mimic, alter or inactiva te the polypeptides of the present invention for use in therapy are also provid ed.
The American Academy of Pediatrics recommends utilizing hospitalizations as an opportunity to provide sexual health screenings for adolescents. This study aimed to describe the current practice of sexual history documentation (SHxD) and sexually transmitted infection (STI) testing among adolescents admitted to a pediatric hospital medicine service. Retrospective cross-sectional study of adolescents (14-19 years old) admitted to the PHM service from 2017-2019 was performed at an academic children's health system. Patient (demographics, history of complex chronic condition, and insurance), hospitalization (length of stay, diagnosis, STI tests ordered/results), and physician (level of training and gender) characteristics were extracted for each encounter. A natural language processing algorithm identified the presence of SHxD. Univariate analysis and multivariable analysis were performed to detect factors associated with SHxD and STI screening. The prevalence of STIs was calculated for those who were tested. Out of 2242 encounters, SHxD and STI testing rates were 40.9% and 17.2%, respectively. Patient gender, race, lack of complex chronic condition, and resident involvement were predictive of SHxD and STI testing. SHxD increased the odds of STI testing significantly (OR 5.06, CI 3.90-6.58). Among those who were tested, the prevalence of STIs was highest for chlamydia (37/329, 11.2%). Overall, sexual health screening rates remain low in the hospital setting and future improvement initiatives are needed.
Mechanical ventilation is essential in intensive care treatment but leads to diaphragmatic atrophy, which in turn contributes to prolonged weaning and increased mortality. One approach to prevent diaphragmatic atrophy while achieving pulmonary ventilation is electrical stimulation of the phrenic nerve. To automize phrenic nerve stimulation resulting in lung protective tidal volumes with lowest possible currents, mathematical models are required. Nerve stimulation models are often complex, so many parameters have to be identified prior to implementation. This paper presents a novel, simplified approach to model phrenic nerve excitation to obtain an individualized patient model using a few data points. The latter is based on the idea that nerve fibers are excited when the electric field exceeds a threshold. The effect of the geometry parameter on the model output was analyzed, and the model was validated with measurement data from a pig trial (RMSE in between 0.44 × 10-2and 1.64 × 10-2for parameterized models). The modeled phrenic nerve excitation behaved similarly to the measured tidal volumes, and thus could be used to develop automated phrenic nerve stimulation systems for lung protective ventilation.
Hispanics in the United States face health disparities for obesity and related medical conditions, such as cardiovascular disease and diabetes. Targeting families to promote healthy lifestyle behaviors has been identified as an effective strategy to prevent obesity. With the importance of familism (family cohesion) among the Hispanic population, a family based intervention is especially desirable as an engaging strategy to promote behaviors that support a healthy weight status and decrease obesity related health disparities for Hispanics. Emerging evidence supports the need to include and target fathers in family based lifestyle behavior interventions. Healthy Dads Healthy Kids (HDHK) is an evidence based program developed in Australia, shown to have significant weight and behavior treatment effects for fathers and their children, compared to controls. The HDHK program is based on Social Cognitive Theory and Family Systems Theory and aims to promote increased physical activity and improved dietary intake for fathers and their children. An important innovation in the program is that fathers and children attend together and are both targeted as agents of behavior change for each other (reciprocal reinforcement) and to participate in fun, family activities together. HDHK was culturally adapted for Hispanic families following the Ecological Validity Model by this research team, with input from a community Hispanic family panel, expert committee and the developer of the HDHK program. The resulting Papás Saludables, Niños Saludables (PSNS) program is a 10-week group-based intervention that meets weekly.

This randomized controlled trial of PSNS is powered to detect a clinically meaningful change in father's weight and children's moderate to vigorous physical activity. The study will also assess other behavioral (dietary intake, sedentary time, screen media use, and parenting practices), psychosocial (familism, acculturation, and co-parenting alliance) and biological (child BMI z-score, father's non-HDL, HgbA1C, and BP) outcomes. Hispanic men with overweight or obesity who are a father figure (biological father, step father, grandfather, adult older brother, etc) to a 5-11 child will be enrolled in the study in waves. Participants are enrolled as a family unit and includes the father, child(ren) (up to 3 siblings) and mother/partner (if available). After screening and baseline data is complete for a wave, the family is randomized to receive a standard of care control or the group-based culturally adapted PSNS. Follow-up assessments will be done at 4 months and 12 months.

The study includes a partnership with the YMCA of Greater Houston to provide a venue for where to deliver the program.
Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Provide patients with appropriate educational materials and counseling to support the quit attempt. 

The patient should set a date to stop smoking. Begin varenicline tablet dosing one week before this date. Alternatively, the patient can begin varenicline tablet dosing and then quit smoking between days 8 and 35 of treatment.

Varenicline tablets should be taken orally after eating and with a full glass of water.

The recommended dose of varenicline tablets are 1 mg twice daily following a 1-week titration as follows: 

Patients should be treated with varenicline tablets for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with varenicline tablets is recommended to further increase the likelihood of long-term abstinence. 

For patients who are sure that they are not able or willing to quit abruptly, consider a gradual approach to quitting smoking with varenicline tablets. Patients should begin varenicline tablets dosing and reduce smoking by 50% from baseline within the first four weeks, by an additional 50% in the next four weeks, and continue reducing with the goal of reaching complete abstinence by 12 weeks. Continue varenicline tablets treatment for an additional 12 weeks, for a total of 24 weeks of treatment. Encourage patients to attempt quitting sooner if they feel ready [see Clinical Studies ( 14.5)]. 

Patients who are motivated to quit, and who did not succeed in stopping smoking during prior varenicline tablets therapy for reasons other than intolerability due to adverse events or who relapsed after treatment, should be encouraged to make another attempt with varenicline tablets once factors contributing to the failed attempt have been identified and addressed. 

Consider a temporary or permanent dose reduction in patients who cannot tolerate the adverse effects of varenicline tablets.
The invention relates to a traditional medicine capsule and the method for preparing the same. Said method comprises following steps: collecting raw materials of dried orange peel, safflower, notoginseng, bark of eucommia, panax ginseng, astragalus root, datura flower, corylifoliumchun and decocted turtle shell, adding water into raw material with the amount of 4-12 times than that of raw material, immersing for 6-18 hours, boiling for three times, each time for 1-3 hours, collecting distillate and storing it, combining distillate, filtering, condensing filtered liquid to make its relative density being 1. 03-1. 04, centrifuging and stewing for 12 hours, filtering, mixing filtrate with said distillate, moderating pH value to 4. 0-6. 0, condensing for the second time at 50 Deg. C to make relative density being 1. 15-1. 25, drying, disintegrating and getting extract; adding micro-crystal fiber with its weight being 2-10% of that of extract and dolomol findings with its weight eing 0. 2-0. 4% of that of extract, mixing, packing into capsule and getting the product. The invention is characterized by good curative effect, stability and controllable quality.
BACKGROUND: Many studies have investigated the association between hypothyroidism and frozen shoulder, but their findings have been inconsistent. Furthermore, earlier research has been primarily observational, which may introduce bias and does not establish a cause-and-effect relationship. To ascertain the causal association, we performed a two-sample bidirectional Mendelian randomization (MR) analysis.
METHODS: We obtained data on "Hypothyroidism" and "Frozen Shoulder" from Summary-level Genome-Wide Association Studies (GWAS) datasets that have been published. The information came from European population samples. The primary analysis utilized the inverse-variance weighted (IVW) method. Additionally, a sensitivity analysis was conducted to assess the robustness of the results.
RESULTS: We ultimately chose 39 SNPs as IVs for the final analysis. The results of the two MR methods we utilized in the investigation indicated that a possible causal relationship between hypothyroidism and frozen shoulder. The most significant analytical outcome demonstrated an odds ratio (OR) of 1.0577 (95% Confidence Interval (CI):1.0057-1.1123), P = 0.029, using the IVW approach. Furthermore, using the MR Egger method as a supplementary analytical outcome showed an OR of 1.1608 (95% CI:1.0318-1.3060), P = 0.017. Furthermore, the results of our sensitivity analysis indicate that there is no heterogeneity or pleiotropy in our MR analysis. In the reverse Mendelian analysis, no causal relationship was found between frozen shoulders and hypothyroidism.
CONCLUSION: Our MR analysis suggests that there may be a causal relationship between hypothyroidism and frozen shoulder.
Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory lesion of the breast. Immunoglobulin G4 (IgG4) associated disease is rare in the breast. In our study, we aimed to evaluate the efficacy of steroid treatment on IgG4 levels in tissue in patients diagnosed with IGM. Between 2008 and 2017, 55 patients diagnosed with IGM in our clinic were included in the study. Demographic, clinical, microbiologic and histopathologic characteristics, treatment modality and recovery time were evaluated retrospectively. Patients were divided into 3 groups according to tissue IgG4 levels: negative (Group I), infrequently and slightly positive (Group II), and highly positive (Group III). Group I patients had a complete response rate of 77.8%. In the rest of the patients (22.2%), insufficient response was detected from the beginning of the treatment. In Group II, the response rate was 91.3% and the permanent success rate after treatment was 87.0%. Although group III patients had a complete response at the beginning (95.65%), they relapsed in a short period of time (26.1%) after discontinuation of steroid treatment. At least one steroid-related side effect was observed in 47 (85.8%) patients in all groups. There is no consensus on the dose and duration of immunosuppressive treatment in IGM. In this study, responses to steroid treatment according to IgG4 concentration in pathologic breast tissue and recurrences after the end of treatment were determined. We think that high IgG4 concentration in the tissue is associated with recurrence and other immunosuppressive drugs should be added as maintenance after steroid treatment.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a composition having high antioxidizing activity from bamboo grass and/or bamboo leaves as raw material.  <P>SOLUTION: The method comprises the following procedure: From a lower aliphatic alcohol extract liquid from bamboo grass and/or bamboo leaves, the alcohol is evaporated and substituted by water followed by removing chlorophyll and making a liquid/liquid partition with diethyl ether or the like and separating an aqueous layer liquid. Ethyl acetate is added to the aqueous layer liquid to make a liquid/liquid partition followed by separating an ethyl acetate layer liquid. Then, the objective luteolin 6-C-glucoside is obtained from the aqueous layer or the ethyl acetate layer. By hydrolyzing the lower aliphatic alcohol extract liquid or fractionated liquid, the yield of the objective compound can be improved.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Cymbalta treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.

The concomitant use of Cymbalta with MAOIs intended to treat depression is contraindicated [see Contraindications (4.1)].

If concomitant treatment of Cymbalta with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Drug Interactions (7.15)].

The concomitant use of Cymbalta with serotonin precursors (such as tryptophan) is not recommended [see Drug Interactions (7.14)].

Treatment with duloxetine and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.